Positive Topline Results from Ph 2/3 Registrational Trial (OptimUM-02) of Darovasertib – Crizotinib combo in 1L HLA-A*02:01-neg Metastatic Uveal Melanoma Announced April 15, 2026
Updated Data from Ph 1b/2 Study of Muzastotug + KEYTRUDA in Late-line Patients with MSS CRC Demonstrate Improved Durability of Response April 15, 2026
Comprehensive response to FDA OPDP submitted regarding issues related to a television advertisement and a podcast for ANKTIVA April 15, 2026
Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor–Resistant Advanced NSCLC Presented April 15, 2026
2-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy in Recurrent Low-Grade Serous Ovarian Cancer presented April 15, 2026
Results from Ph 2 IMGN853-0420 trial show ORR of 62.7% with ELAHERE + chemo followed by ELAHERE monotherapy in patients with ≥50% FRα-expressing PSOC April 15, 2026
Neoadjuvant Anbenitamab Meets Primary Endpoint in Ph 3 HER2-Positive Breast Cancer Trial April 7, 2026
Imfinzi + Imjudo combined with lenvatinib and TACE demonstrated a statistically significant PFS improvement in embolisation-eligible unresectable liver cancer in EMERALD-3 Ph 3 trial April 7, 2026
OS beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of Ph 2 THIO-101 trial in NSCLC reported April 7, 2026
Ph 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint of Spleen Volume Reduction but not Abs-TSS March 31, 2026
Updated Ph 2 Data Showing Continued Improvement in Median OS with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer Reported March 31, 2026
Namodenoson Positive Data in Ph 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient Announced March 31, 2026
Positive Topline Results from Ph 2 PANOVA-4 Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer Announced March 31, 2026
ZEGFROVY® (Sunvozertinib) Shows Antitumor Activity in 1L NSCLC Patients with EGFR PACC or Other Uncommon Mutations March 31, 2026
Mature median OS data from ongoing ACCENT clinical trial of narmafotinib + chemo in advanced pancreatic cancer announced March 24, 2026
Positive Ph 3 Results from WU-KONG28 Study of ZEGFROVY® (Sunvozertinib) vs. Chemo in 1L NSCLC with exon20ins Mutation Announced March 24, 2026
Positive Ph 1 expansion data for EpCAM PROBODY® ADC, varsetatug masetecan (Varseta-M) in late-line metastatic CRC announced March 24, 2026
Ph 1a data of TOS-358 in heavily pretreated patients with PI3Kα-mutant metastatic breast cancer and other solid tumors presented March 24, 2026
Data from Ph 1/2 ReDiscover trial of 400mg BID zovegalisib (RLY-2608) + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer announced March 24, 2026
Extended long-term survival observed in Ph 2a trial in advanced NSCLC treated with aglatimagene besadenovec (aglatimagene or CAN-2409) March 24, 2026
Primary endpoint met in Ph 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile March 24, 2026
TALZENNA Plus XTANDI Significantly Improves Radiographic PFS in Metastatic Prostate Cancer March 24, 2026
